TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for HYQVIA® as a maintenance therapy for patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Please find the press release here:
Other Articles You May Like
August 5, 2026
Claire, Recipient of the Benson Research Fellowship: One Step Closer to a Cure
For Dr. Claire Bergstrom Johnson, becoming a scientist wasn't just a career choice—it was personal. When her…
August 3, 2026
Julie Bell’s Clinical Trial Journey: Why She’d Participate Again
In rare disease communities like ours, progress in drug development is often slow, in part…
July 29, 2026
GBS|CIDP Foundation Partners with UNITAR to Advance Global Plasma Access
The Foundation is proud to officially partner with United Nations Institute for Training and Research…